Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Jan;18(1):18-25.
doi: 10.3747/co.v18i1.708.

Oxaliplatin: a review in the era of molecularly targeted therapy

T Alcindor  1 , N Beauger
Affiliations

Oxaliplatin: a review in the era of molecularly targeted therapy

T Alcindor et al. Curr Oncol. 2011 Jan.

Abstract

Objective: To review preclinical and clinical data for oxaliplatin in the current context of molecularly targeted therapy.

Methods of study selection: We searched the PubMed and PubChem databases by combining the search terms "oxaliplatin" or "platinum" or both, with "clinical trials," "pharmacokinetics," and "pharmacodynamics."

Data extraction and synthesis: Oxaliplatin has a complicated pharmacokinetic profile, with activity against digestive cancers in particular. It has several mechanisms of action, but cancer cells can develop resistance. Real or potential synergism has been observed when oxaliplatin is combined with other cytotoxic agents or molecularly targeted agents. Peripheral neuropathy is a prominent toxic effect.

Conclusions: Oxaliplatin lends itself to further clinical research in combination with molecularly targeted therapy.

Keywords: Oxaliplatin; chemotherapy; mechanism of action; targeted therapy.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Ibrahim A, Hirschfeld S, Cohen MH, Griebel DJ, Williams GA, Pazdur R. fda drug approval summaries: oxaliplatin. Oncologist. 2004;9:8–12. doi: 10.1634/theoncologist.9-1-8. - DOI - PubMed
    1. Raymond E, Chaney SG, Taamma A, Cvitkovic E. Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol. 1998;9:1053–71. doi: 10.1023/A:1008213732429. - DOI - PubMed
    1. United States, National Institutes of Health, National Cancer Institute (nci) Home > NCI Drug Dictionary > O > Oxaliplatin [Web resource] Bethesda, MD: nci; n.d. [Available at: www.cancer.gov/drugdictionary/?CdrID=42374; cited April 1, 2010]
    1. Faivre S, Chan D, Salinas R, Woynarowska B, Woynarowski JM. dna strand breaks and apoptosis induced by oxaliplatin in cancer cells. Biochem Pharmacol. 2003;66:225–37. doi: 10.1016/S0006-2952(03)00260-0. - DOI - PubMed
    1. Zwelling LA, Anderson T, Kohn KW. dna-protein and dna interstrand cross-linking by cis- and trans-platinum(ii) diamminedichloride in L1210 mouse leukemia cells and relation to cytotoxicity. Cancer Res. 1979;39:365–9. - PubMed